Renal effects of targeted anticancer therapies

Abstract

The use of novel targeted anticancer agents has led to overall improvement in the prognosis of many patients affected by various malignancies, but has also been associated with an increased risk of poorly characterized toxic effects to different organs, including the kidneys. The high prevalence of kidney impairment in the general population complicates the issue further. Nephrologists most frequently work with patients with cancer when they are asked to investigate kidney function to assess the need for dose adjustments in anticancer therapy. A thorough knowledge of the renal safety profile of novel life-prolonging anticancer therapies, specific features of their metabolism, and pharmacokinetic and pharmacodynamic properties (under normal circumstances as well as in the setting of renal replacement therapy) is, therefore, necessary to preserve kidney function as far as possible and to ensure optimum treatment. In this Review we summarize the present knowledge of renal toxic effects from novel targeted anticancer agents and discuss whether the management of patients' treatment needs to be modified. We also advocate the development of a new onconephrology subspeciality.

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

“…1 Drugs that target specific cancer genes or proteins are extremely effective but also suffer from nephrotoxicity. 1,2 Manipulating the immune system represents an attractive therapy as our understanding of the concept of cancer immunoediting has evolved. 3 Immunoediting characterizes the interaction of tumor cells with the immune system and consists of three phases.…”

The safety of monoclonal antibodies for treatment of colorectal cancer

“…In absence of VEGF-A maturation of podocytes and endothelial cells is impaired leading to glomerular loss. Whether bevacizumab associated proteinuria may predict clinical outcome has still to be elucidated [44]. In a metaanalysis comprising six randomized trials the relative risk for high-grade proteinuria among mCRC patients treated with bevacizumab was 2.52 (95% CI, 1.…”

Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies

“…Another key point to keep in mind is that, beyond cisplatin, a number of other anticancer agents (eg, targeted agents and immune checkpoint inhibitors) may induce glomerular injury, tubulopathies as well as interstitial nephritis. [23][24][25] Thus, since almost all patients with cancer on active treatment undergo a number of CECT scans, the risk of an increased nephrotoxicity is particularly high, not to take into account the fact that patients on clinical trials usually undergo very closely repeated iodinated CM administration in order to monitor the activity of experimental treatments.…”